You are here

  • Home
  • Online First
  • Ceftriaxone to enable paediatric outpatient antimicrobial treatment (OPAT) in neonates

Article Text

Article menu
Download PDFPDF
Letter
Ceftriaxone to enable paediatric outpatient antimicrobial treatment (OPAT) in neonates
  1. Hayley King1,2,
  2. Kelly Walsgrave1,
  3. Sanjay Patel3,
  4. Helen Green3,
  5. Paul Moriarty4,
  6. Neil Dawson4,
  7. Mairi Gillespie5,
  8. David Porter6,
  9. Claire Crouch6,
  10. Jolanta Bernatoniene1,2
  1. 1University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
  2. 2University of Bristol, Bristol, UK
  3. 3University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, UK
  4. 4Royal Belfast Hospital for Sick Children, Belfast, UK
  5. 5Sheffield Children's NHS Foundation Trust, Sheffield, UK
  6. 6Alder Hey Children’s NHS Foundation Trust, Liverpool, Merseyside, UK
  1. Correspondence to Dr Hayley King; hevans{at}doctors.org.uk

https://doi.org/10.1136/archdischild-2024-327621

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    This letter highlights the experience of once daily (OD) parenteral ceftriaxone in neonates referred to OPAT Service at the Children’s Hospitals in Bristol, Southampton, Belfast, Alder Hey and Sheffield, and proposes that, with appropriate monitoring, this is a safe and effective treatment strategy.

    As OD broad-spectrum antimicrobial with good central nervous system penetration, ceftriaxone has practical benefits over other antibiotics used to treat bacterial infections in babies and children, including reduced length of hospital stay due to administration in the community. It is generally well tolerated, with main adverse events known to include reversible cholelithiasis.1 It must never be given to infants receiving calcium or calcium-containing solutions, including total parenteral nutrition due to …

    View Full Text

    Footnotes

    • X @doctorsanjay

    • Contributors All authors have contributed data and approved this letter.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.